|
| Id | Term | value | Q value | Gene |
|
| hsa04933 | Age-rage signaling pathway in diabetic complications | 9.74E − 16 | 8.41E − 14 | MMP2/BCL2/CCL2/COL3A1/SELE/IL6/MAPK1/MAPK14/MAPK8/NOS3/PIM1/THBD/F3/JUN/TNF/VCAM1/VEGFA |
| hsa05418 | Fluid shear stress and atherosclerosis | 1.86E − 14 | 8.03E − 13 | MMP2/BCL2/CCL2/TP53/SELE/GSTM1/HMOX1/IFNG/MAPK14/MAPK8/NQO1/NOS3/THBD/PLAT/JUN/TNF/VCAM1/VEGFA |
| hsa05215 | Prostate cancer | 1.01E − 09 | 2.90E − 08 | AR/BCL2/CDK2/TP53/EGFR/GSK3B/IGF1R/MAPK1/EGF/MMP3/PLAT/PLAU |
| hsa04020 | Calcium signaling pathway | 5.20E − 09 | 1.12E − 07 | HTR2A/ADRA1A/ADRA1B/ADRB2/DRD1/EGFR/PRKACA/CHRM1/CHRM2/CHRM3/CHRNA7/NOS2/NOS3/PTGER3/PPP3CA |
| hsa04657 | IL-17 signaling pathway | 9.60E − 09 | 1.66E − 07 | CCL2/GSK3B/IFNG/IL6/MMP1/MAPK1/MAPK14/MAPK8/MMP3/JUN/TNF |
| hsa01522 | Endocrine resistance | 1.50E − 08 | 2.16E − 07 | MMP2/BCL2/TP53/EGFR/ESR2/IGF1R/MAPK1/MAPK14/MAPK8/PRKACA/JUN |
| hsa04926 | Relaxin signaling pathway | 2.73E − 08 | 3.37E − 07 | MMP2/COL3A1/EGFR/MMP1/MAPK1/MAPK14/MAPK8/PRKACA/NOS2/NOS3/JUN/VEGFA |
| hsa04659 | Th17 cell differentiation | 3.81E − 08 | 4.11E − 07 | AHR/IFNG/IL2/IL6/MAPK1/MAPK14/MAPK8/RXRA/RXRB/PPP3CA/JUN |
| hsa04066 | HIF-1 signaling pathway | 4.62E − 08 | 4.43E − 07 | BCL2/EGFR/HMOX1/IGF1R/IFNG/IL6/MAPK1/NOS2/NOS3/EGF/VEGFA |
| hsa04080 | Neuroactive ligand-receptor interaction | 5.74E − 08 | 4.96E − 07 | HTR2A/ADRA1A/ADRA1B/ADRA2A/ADRA2C/ADRB2/OPRD1/DRD1/GABRA1/NR3C1/CHRM1/CHRM2/CHRM3/OPRM1/CHRNA7/ADCYAP1/PTGER3/F2 |
| hsa04151 | PI3K-Akt signaling pathway | 1.06E − 07 | 8.33E − 07 | BCL2/CDK2/TP53/EGFR/GSK3B/MET/IGF1R/IL2/IL6/MAPK1/CHRM1/CHRM2/NOS3/PIK3CG/EGF/RBL2/RXRA/VEGFA |
| hsa05142 | Chagas disease (American trypanosomiasis) | 2.59E − 07 | 1.86E − 06 | CCL2/IFNG/IL2/IL6/MAPK1/MAPK14/MAPK8/NOS2/JUN/TNF |
| hsa01521 | EGFR tyrosine kinase inhibitor resistance | 2.92E − 07 | 1.94E − 06 | BCL2/EGFR/GSK3B/MET/IGF1R/IL6/MAPK1/EGF/VEGFA |
| hsa05219 | Bladder cancer | 3.88E − 07 | 2.39E − 06 | MMP2/TP53/EGFR/MMP1/MAPK1/EGF/VEGFA |
| hsa04022 | cGMP-PKG signaling pathway | 4.76E − 07 | 2.74E − 06 | ADRA1A/ADRA1B/ADRA2A/ADRA2C/ADRB2/KCNMA1/PDE3A/OPRD1/MAPK1/NOS3/PIK3CG/PPP3CA |
| hsa04915 | Estrogen signaling pathway | 5.25E − 07 | 2.83E − 06 | MMP2/BCL2/CTSD/EGFR/ESR2/MAPK1/PRKACA/OPRM1/NOS3/PGR/JUN |
| hsa04668 | TNF signaling pathway | 6.25E − 07 | 3.18E − 06 | CCL2/SELE/IL6/MAPK1/MAPK14/MAPK8/MMP3/JUN/TNF/VCAM1 |
| hsa05202 | Transcriptional misregulation in cancer | 1.51E − 06 | 7.20E − 06 | TP53/CCNA2/MET/IGF1R/IL6/MPO/PPARG/RXRA/RXRB/MMP3/PLAT/PLAU |
| hsa05144 | Malaria | 1.58E − 06 | 7.20E − 06 | CCL2/SELE/MET/IFNG/IL6/TNF/VCAM1 |
| hsa04660 | T cell receptor signaling pathway | 3.06E − 06 | 1.32E − 05 | GSK3B/IFNG/IL2/MAPK1/MAPK14/MAPK8/PPP3CA/JUN/TNF |
|
